MAUDE Adverse Event Report: SOFRADIM PRODUCTION SAS MESH SOFRADIM - PARIETEX¿ COMPOSITE MESH; MESH, SURGICAL, POLYMERIC

Model Number PCO1510OS

Device Problems Migration or Expulsion of Device (1395); Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Abscess (1690); Adhesion(s) (1695); Bacterial Infection (1735); Fistula (1862); Unspecified Infection (1930); Inflammation (1932); Pain (1994); Staphylococcus Aureus (2058); Scar Tissue (2060); Scarring (2061); Hernia (2240); Injury (2348); Obstruction/Occlusion (2422); Fluid Discharge (2686); No Code Available (3191); Unspecified Tissue Injury (4559); Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)

Event Type  Injury  

Manufacturer Narrative

If information is provided in the future, a supplemental report will be issued.

Event Description

The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a recurrent incisional hernia.It was reported that after implant, the patient experienced recurrent abdominal wall hernias, superficial fistulas, intra-abdominal adhesions by the transverse colon, thickened dense fascia, scarring, and abscess formation on mesh.Post-operative treatment included recurrent abdominal wall hernia repair with new mesh, resection of inferior thickened abdominal wall with scarring, excision of anterior abdominal wall fistulas, partial removal of muscular rectus layer, mesh revision surgery, and removal of abdominal wall skin/subcutaneous area.

Event Description

The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a recurrent incisional hernia.It was reported that after implant, the patient experienced recurrent abdominal wall hernias, superficial fistulas, intra-abdominal adhesions by the transverse colon, thickened dense fascia, scarring, and abscess formation on mesh.Post-operative treatment included recurrent abdominal wall hernia repair with ethicon vicryl knitted mesh and bard xenmatrix mesh, resection of inferior thickened abdominal wall with scarring, excision of anterior abdominal wall fistulas, partial removal of muscular rectus layer, mesh revision surgery, and removal of abdominal wall skin/subcutaneous area.

Manufacturer Narrative

This information was received as a part of an extensive mesh litigation submission to medtronic.The fda was notified of this large complaint receipt.Due to the volume of complaint information received by medtronic, this resulted in a report beyond the 30 day target.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.

Event Description

The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a recurrent incisional hernia.It was reported that after implant, the patient experienced multiple recurrent abdominal wall hernias, numerous fistulas, intra-abdominal adhesions by the transverse colon, thickened dense fascia, scarring, long-standing fistulas drainage of the anterior abdominal wall, chronic mrsa infection, abscess formation on mesh and inflammatory reaction.Post-operative treatment included recurrent abdominal wall hernia repair with ethicon vicryl knitted mesh and bard xenmatrix mesh, resection of inferior thickened abdominal wall with scarring, excision of anterior abdominal wall fistulas, partial removal of muscular rectus layer, mesh revision surgery, removal of abdominal wall skin/subcutaneous area and laparotomy with lysis of adhesions.

Manufacturer Narrative

This information was received as a part of an extensive mesh litigation submission to medtronic.The fda was notified of this large complaint receipt.Due to the volume of complaint information received by medtronic, this resulted in a report beyond the 30 day target.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.

Manufacturer Narrative

Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.

Event Description

The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a recurrent incisional hernia.It was reported that after implant, the patient experienced multiple recurrent abdominal wall hernias, numerous fistulas, intra-abdominal adhesions by the transverse colon, thickened dense fascia, scarring, long-standing fistulas drainage of the anterior abdominal wall, chronic mrsa infection, abscess formation on mesh, infection, soft tissue endometriosis, pain, small bowel obstruction, bunched up pieces of mesh, and inflammatory reaction.Post-operative treatment included recurrent abdominal wall hernia repair with ethicon vicryl knitted mesh and bard xenmatrix mesh, resection of inferior thickened abdominal wall with scarring, excision of anterior abdominal wall fistulas, partial removal of muscular rectus layer, mesh revision surgery, removal of abdominal wall skin/subcutaneous area and laparotomy with lysis of adhesions.

Event Description

The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of a recurrent incisional hernia.It was reported that after implant, the patient experienced multiple recurrent abdominal wall hernias, numerous fistulas, intra-abdominal adhesions by the transverse colon, thickened dense fascia, scarring, long-standing fistulas drainage of the anterior abdominal wall, chronic mrsa infection, abscess formation on mesh, infection, soft tissue endometriosis, pain, small bowel obstruction, bunched up pieces of mesh, and inflammatory reaction.Post-operative treatment included recurrent abdominal wall hernia repair with ethicon vicryl knitted mesh and bard xenmatrix mesh, resection of inferior thickened abdominal wall with scarring, excision of anterior abdominal wall fistulas, partial removal of muscular rectus layer, mesh revision surgery, removal of abdominal wall skin/subcutaneous area, use of drain, medications, removal of mesh, and laparotomy with lysis of adhesions.

Manufacturer Narrative

Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.

• Brand Name: MESH SOFRADIM - PARIETEX¿ COMPOSITE MESH
• Type of Device: MESH, SURGICAL, POLYMERIC
• Manufacturer (Section D): SOFRADIM PRODUCTION SAS; 116 avenue du formans; trevoux 01600 ; FR 01600
• Manufacturer (Section G): SOFRADIM PRODUCTION SAS; 116 avenue du formans; trevoux 01600 ; FR 01600
• Manufacturer Contact: justin ellis ; 8200 coral sea st ne; mounds view,mn, CO 55112 ; 7635265677
• MDR Report Key: 8499553
• MDR Text Key: 141466203
• Report Number: 9615742-2019-01170
• Device Sequence Number: 1
• Product Code: FTL
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: K050187
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Consumer
• Reporter Occupation: Non-Healthcare Professional
• Type of Report: Initial,Followup,Followup,Followup,Followup
• Report Date: 09/30/2022

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Expiration Date: 07/31/2014
• Device Model Number: PCO1510OS
• Device Catalogue Number: PCO1510OS
• Device Lot Number: PJH00001
• Was Device Available for Evaluation?: No
• Initial Date Manufacturer Received: 03/20/2019
• Initial Date FDA Received: 04/10/2019
• Supplement Dates Manufacturer Received: 05/15/2019; 05/15/2019; 02/09/2022; 09/21/2022
• Supplement Dates FDA Received: 08/30/2019; 10/11/2019; 03/09/2022; 10/01/2022
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Sex: Female
• Patient Weight: 109 KG